is seeking a biomarker for measuring disease progression in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s Disease). The proposed biomarker should meet the criteria outlined in the Detailed Description & Requirements of the challenge. Up to 1 million USD will be awarded for a validated ALS biomarker capable of being used in Phase II clinical trials to determine treatment efficacy.
Any biological correlate (e.g. body fluids, imaging, electrophysiological examination etc.) can qualify as a solution, as long as the Solver provides a detailed description and validation for it.
There are no specific requirements as to the method by which the Solver delivers a result. As an example, the validation could be based on clinical or experimental work, or on statistical analysis of existing trials data. However, the Solver must provide statistically significant results as proof for the validity of the solution. All biological correlate(s) need to be thoroughly characterized. The Solver's proposal should also be accompanied by a solid scientific rationale supported by literature precedents. If Solvers are facing difficulties getting access to necessary information, they can approach the Seeker. The Seeker will help if he sees fit to do so.
The deadline for this prize is rolling such that submissions will be considered as they are received and, at the discretion of the Seeker, the first submission which meets all of the challenge criteria will be awarded the prize. Unlike many other InnoCentive Seekers, Prize4Life makes no IP claims as to the solution submitted and our IP policy is explained in more detail in the solver agreement.